Treatment with astragaloside IV reduced blood glucose, regulated blood lipids, and protected liver function in diabetic rats

Objectives To investigate the effects of astragaloside IV on blood glucose, blood lipids, and liver function in diabetic rats. Methods Fifty diabetic rats were randomly placed into five groups (n = 10 each): the diabetes mellitus (DM) group received intragastric saline, the metformin hydrochloride g...

Full description

Saved in:
Bibliographic Details
Published inJournal of international medical research Vol. 49; no. 3; p. 300060519841165
Main Author Han, Dong
Format Journal Article
LanguageEnglish
Published London, England SAGE Publications 01.03.2021
Sage Publications Ltd
SAGE Publishing
Subjects
Online AccessGet full text

Cover

Loading…
Abstract Objectives To investigate the effects of astragaloside IV on blood glucose, blood lipids, and liver function in diabetic rats. Methods Fifty diabetic rats were randomly placed into five groups (n = 10 each): the diabetes mellitus (DM) group received intragastric saline, the metformin hydrochloride group received intragastric metformin hydrochloride, and the astragaloside-30, -60, and -120 groups received intragastric astragaloside 30 mg/kg, 60 mg/kg, and 120 mg/kg for 28 days, respectively. Ten non-diabetic rats received intragastric saline as controls. Results Relative to the DM group, fasting blood glucose, triglyceride, total cholesterol, serum alanine transaminase, and serum aspartate aminotransferase levels decreased in the astragaloside-60 and astragaloside-120 groups; serum alkaline phosphatase decreased solely in the astragaloside-120 group. Serum superoxide dismutase (SOD), glutathione (GSH-Px), and catalase (CAT) levels were elevated, while maleic dialdehyde (MDA) decreased in the astragaloside-120 group, relative to the DM group. Relative to the DM group, the liver index and liver cell apoptosis rate were reduced, while histopathological changes in liver tissue were ameliorated in the astragaloside groups; moreover, liver tissue SOD, GSH-Px, and CAT levels were increased, while liver tissue MDA was reduced. Conclusions Astragaloside IV can lower blood glucose, regulate blood lipids, and protect liver function in diabetic rats.
AbstractList Objectives To investigate the effects of astragaloside IV on blood glucose, blood lipids, and liver function in diabetic rats. Methods Fifty diabetic rats were randomly placed into five groups (n = 10 each): the diabetes mellitus (DM) group received intragastric saline, the metformin hydrochloride group received intragastric metformin hydrochloride, and the astragaloside-30, -60, and -120 groups received intragastric astragaloside 30 mg/kg, 60 mg/kg, and 120 mg/kg for 28 days, respectively. Ten non-diabetic rats received intragastric saline as controls. Results Relative to the DM group, fasting blood glucose, triglyceride, total cholesterol, serum alanine transaminase, and serum aspartate aminotransferase levels decreased in the astragaloside-60 and astragaloside-120 groups; serum alkaline phosphatase decreased solely in the astragaloside-120 group. Serum superoxide dismutase (SOD), glutathione (GSH-Px), and catalase (CAT) levels were elevated, while maleic dialdehyde (MDA) decreased in the astragaloside-120 group, relative to the DM group. Relative to the DM group, the liver index and liver cell apoptosis rate were reduced, while histopathological changes in liver tissue were ameliorated in the astragaloside groups; moreover, liver tissue SOD, GSH-Px, and CAT levels were increased, while liver tissue MDA was reduced. Conclusions Astragaloside IV can lower blood glucose, regulate blood lipids, and protect liver function in diabetic rats.
Objectives To investigate the effects of astragaloside IV on blood glucose, blood lipids, and liver function in diabetic rats. Methods Fifty diabetic rats were randomly placed into five groups (n = 10 each): the diabetes mellitus (DM) group received intragastric saline, the metformin hydrochloride group received intragastric metformin hydrochloride, and the astragaloside-30, -60, and -120 groups received intragastric astragaloside 30 mg/kg, 60 mg/kg, and 120 mg/kg for 28 days, respectively. Ten non-diabetic rats received intragastric saline as controls. Results Relative to the DM group, fasting blood glucose, triglyceride, total cholesterol, serum alanine transaminase, and serum aspartate aminotransferase levels decreased in the astragaloside-60 and astragaloside-120 groups; serum alkaline phosphatase decreased solely in the astragaloside-120 group. Serum superoxide dismutase (SOD), glutathione (GSH-Px), and catalase (CAT) levels were elevated, while maleic dialdehyde (MDA) decreased in the astragaloside-120 group, relative to the DM group. Relative to the DM group, the liver index and liver cell apoptosis rate were reduced, while histopathological changes in liver tissue were ameliorated in the astragaloside groups; moreover, liver tissue SOD, GSH-Px, and CAT levels were increased, while liver tissue MDA was reduced. Conclusions Astragaloside IV can lower blood glucose, regulate blood lipids, and protect liver function in diabetic rats.
To investigate the effects of astragaloside IV on blood glucose, blood lipids, and liver function in diabetic rats.OBJECTIVESTo investigate the effects of astragaloside IV on blood glucose, blood lipids, and liver function in diabetic rats.Fifty diabetic rats were randomly placed into five groups (n = 10 each): the diabetes mellitus (DM) group received intragastric saline, the metformin hydrochloride group received intragastric metformin hydrochloride, and the astragaloside-30, -60, and -120 groups received intragastric astragaloside 30 mg/kg, 60 mg/kg, and 120 mg/kg for 28 days, respectively. Ten non-diabetic rats received intragastric saline as controls.METHODSFifty diabetic rats were randomly placed into five groups (n = 10 each): the diabetes mellitus (DM) group received intragastric saline, the metformin hydrochloride group received intragastric metformin hydrochloride, and the astragaloside-30, -60, and -120 groups received intragastric astragaloside 30 mg/kg, 60 mg/kg, and 120 mg/kg for 28 days, respectively. Ten non-diabetic rats received intragastric saline as controls.Relative to the DM group, fasting blood glucose, triglyceride, total cholesterol, serum alanine transaminase, and serum aspartate aminotransferase levels decreased in the astragaloside-60 and astragaloside-120 groups; serum alkaline phosphatase decreased solely in the astragaloside-120 group. Serum superoxide dismutase (SOD), glutathione (GSH-Px), and catalase (CAT) levels were elevated, while maleic dialdehyde (MDA) decreased in the astragaloside-120 group, relative to the DM group. Relative to the DM group, the liver index and liver cell apoptosis rate were reduced, while histopathological changes in liver tissue were ameliorated in the astragaloside groups; moreover, liver tissue SOD, GSH-Px, and CAT levels were increased, while liver tissue MDA was reduced.RESULTSRelative to the DM group, fasting blood glucose, triglyceride, total cholesterol, serum alanine transaminase, and serum aspartate aminotransferase levels decreased in the astragaloside-60 and astragaloside-120 groups; serum alkaline phosphatase decreased solely in the astragaloside-120 group. Serum superoxide dismutase (SOD), glutathione (GSH-Px), and catalase (CAT) levels were elevated, while maleic dialdehyde (MDA) decreased in the astragaloside-120 group, relative to the DM group. Relative to the DM group, the liver index and liver cell apoptosis rate were reduced, while histopathological changes in liver tissue were ameliorated in the astragaloside groups; moreover, liver tissue SOD, GSH-Px, and CAT levels were increased, while liver tissue MDA was reduced.Astragaloside IV can lower blood glucose, regulate blood lipids, and protect liver function in diabetic rats.CONCLUSIONSAstragaloside IV can lower blood glucose, regulate blood lipids, and protect liver function in diabetic rats.
To investigate the effects of astragaloside IV on blood glucose, blood lipids, and liver function in diabetic rats. Fifty diabetic rats were randomly placed into five groups (n = 10 each): the diabetes mellitus (DM) group received intragastric saline, the metformin hydrochloride group received intragastric metformin hydrochloride, and the astragaloside-30, -60, and -120 groups received intragastric astragaloside 30 mg/kg, 60 mg/kg, and 120 mg/kg for 28 days, respectively. Ten non-diabetic rats received intragastric saline as controls. Relative to the DM group, fasting blood glucose, triglyceride, total cholesterol, serum alanine transaminase, and serum aspartate aminotransferase levels decreased in the astragaloside-60 and astragaloside-120 groups; serum alkaline phosphatase decreased solely in the astragaloside-120 group. Serum superoxide dismutase (SOD), glutathione (GSH-Px), and catalase (CAT) levels were elevated, while maleic dialdehyde (MDA) decreased in the astragaloside-120 group, relative to the DM group. Relative to the DM group, the liver index and liver cell apoptosis rate were reduced, while histopathological changes in liver tissue were ameliorated in the astragaloside groups; moreover, liver tissue SOD, GSH-Px, and CAT levels were increased, while liver tissue MDA was reduced. Astragaloside IV can lower blood glucose, regulate blood lipids, and protect liver function in diabetic rats.
Author Han, Dong
Author_xml – sequence: 1
  givenname: Dong
  orcidid: 0000-0002-5945-4731
  surname: Han
  fullname: Han, Dong
  email: handong6717@163.com
  organization: Department of Pharmacy, Cangzhou Central Hospital, Cangzhou, China
BackLink https://www.ncbi.nlm.nih.gov/pubmed/33706619$$D View this record in MEDLINE/PubMed
BookMark eNp9ks1rFTEUxYNU7Gt170oCblx0NN-T2QhS_HhQcFPdhkySmeaRN3kmmYrQP74ZX1vtA10F7vmdw-HenICjKU4OgJcYvcW4bd8hihASiONOMowFfwJWmLW0IXV-BFaL3Cz6MTjJeYMQI4KTZ-CY0hYJgbsVuLlMTpetmwr86csV1LkkPeoQs7cOrr_D5OxsnIV9iNHCMcwmZndWx-McdHkQgt95m8-gnizcpVicWbTgr12CwzyZ4uME_QSt170r3sCkS34Ong46ZPfi7j0F3z59vDz_0lx8_bw-_3DRGE5kaQY9yFajbrCCDrgTHcVMSN63xAlJNCISEy0JHwiiHbNd30uNhOHIcuqk6egpWO9zbdQbtUt-q9MvFbVXvwcxjUqnWio41VHiGLJOip4xQ2RviR3Y0EnDuWQtrlnv91m7ud86a-rmkg6PQh8rk79SY7xWEgvBMKoBb-4CUvwxu1zU1mfjQtCTi3NWhCNMhJSMV_T1AbqJc5rqqhaqZS2jklXq1d-NHqrcH7kCYg-YFHNOblDGF71cpBb0QWGklt-kDn9TNaID4332fyzN3pL16P7U_Sd_CwJ316A
CitedBy_id crossref_primary_10_1002_ptr_8432
crossref_primary_10_1007_s11356_023_25766_3
crossref_primary_10_3389_fendo_2023_1190827
crossref_primary_10_1016_j_jchromb_2024_124194
crossref_primary_10_3390_ijms241813762
crossref_primary_10_1002_ptr_8229
crossref_primary_10_1097_IM9_0000000000000139
crossref_primary_10_1016_j_heliyon_2024_e26863
crossref_primary_10_1515_biol_2022_0886
crossref_primary_10_1016_j_phymed_2024_156165
crossref_primary_10_1007_s10735_024_10252_y
Cites_doi 10.1016/j.bbadis.2017.03.006
10.1016/j.dsx.2017.12.029
10.1016/j.bcp.2008.06.020
10.1142/S0192415X1750063X
10.1016/j.jsps.2017.04.009
10.2147/DDDT.S152489
10.1111/fcp.12232
10.3892/ijmm.2016.2555
10.2337/dci15-0012
10.3892/etm.2016.3629
10.1155/2017/8095926
10.2147/DDDT.S166525
10.2147/DDDT.S171286
10.1016/S0140-6736(17)30058-2
10.1159/000486166
10.1016/j.freeradbiomed.2018.02.022
10.1016/j.ijcard.2018.09.023
10.4314/ajtcam.v11i4.1
10.1016/j.fct.2018.05.029
10.1186/s12933-017-0604-9
10.1016/j.biopha.2018.08.013
10.3892/etm.2016.3194
10.1038/aps.2016.175
10.1186/s12906-017-1930-x
10.3389/fphys.2018.00015
10.1177/0300060518778711
10.1159/000464122
10.2337/db09-9028
10.3109/0886022X.2013.867798
10.1038/cdd.2017.61
10.1001/jama.2014.15298
ContentType Journal Article
Copyright The Author(s) 2021
The Author(s) 2021. This work is licensed under the Creative Commons Attribution – Non-Commercial License https://creativecommons.org/licenses/by-nc/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
The Author(s) 2021 2019 SAGE Publications
Copyright_xml – notice: The Author(s) 2021
– notice: The Author(s) 2021. This work is licensed under the Creative Commons Attribution – Non-Commercial License https://creativecommons.org/licenses/by-nc/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
– notice: The Author(s) 2021 2019 SAGE Publications
DBID AFRWT
AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
3V.
7X7
7XB
8FI
8FJ
8FK
ABUWG
AFKRA
AZQEC
BENPR
CCPQU
DWQXO
FYUFA
GHDGH
K9.
M0S
PHGZM
PHGZT
PIMPY
PKEHL
PQEST
PQQKQ
PQUKI
7X8
5PM
DOA
DOI 10.1177/0300060519841165
DatabaseName Sage Journals GOLD Open Access 2024
CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
ProQuest Central (Corporate)
Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
ProQuest Hospital Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni)
ProQuest Central UK/Ireland
ProQuest Central Essentials
ProQuest Central
ProQuest One Community College
ProQuest Central
Health Research Premium Collection
Health Research Premium Collection (Alumni)
ProQuest Health & Medical Complete (Alumni)
ProQuest Health & Medical Collection
ProQuest Central Premium
ProQuest One Academic
Publicly Available Content Database
ProQuest One Academic Middle East (New)
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Academic
ProQuest One Academic UKI Edition
MEDLINE - Academic
PubMed Central (Full Participant titles)
DOAJ Directory of Open Access Journals
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
Publicly Available Content Database
ProQuest One Academic Middle East (New)
ProQuest Central Essentials
ProQuest One Academic Eastern Edition
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
ProQuest One Community College
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
ProQuest Hospital Collection (Alumni)
ProQuest Central
ProQuest Health & Medical Complete
Health Research Premium Collection
ProQuest One Academic UKI Edition
Health and Medicine Complete (Alumni Edition)
ProQuest Central Korea
ProQuest Central (New)
ProQuest One Academic
ProQuest One Academic (New)
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList Publicly Available Content Database

MEDLINE - Academic
MEDLINE

Database_xml – sequence: 1
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 3
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
– sequence: 4
  dbid: AFRWT
  name: Sage Journals GOLD Open Access 2024
  url: http://journals.sagepub.com/
  sourceTypes: Publisher
– sequence: 5
  dbid: 7X7
  name: Health & Medical Collection
  url: https://search.proquest.com/healthcomplete
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Pharmacy, Therapeutics, & Pharmacology
EISSN 1473-2300
ExternalDocumentID oai_doaj_org_article_932e40de86b44c28bd2df4f98c558471
PMC8166410
33706619
10_1177_0300060519841165
10.1177_0300060519841165
Genre Journal Article
GroupedDBID ---
.55
.GJ
01A
0R~
29K
2WC
44B
53G
54M
5GY
5RE
5VS
7X7
8FI
8FJ
AABQO
AACKU
AAFWJ
AAGGD
AAJIQ
AAJOX
AAJPV
AAJQC
AANSI
AAPEO
AAQQG
AAQXH
AASGM
AAXOT
AAYTG
AAZBJ
ABAFQ
ABAWP
ABDWY
ABHKI
ABJNI
ABNCE
ABPGX
ABQKF
ABQXT
ABUWG
ABVFX
ABXGC
ABYTW
ACARO
ACFMA
ACFYK
ACGBL
ACGFS
ACLHI
ACROE
ADBBV
ADEIA
ADMPF
ADOGD
ADQSQ
ADTBJ
ADUKL
AECVZ
AEFTW
AENEX
AERKM
AEUHG
AEWDL
AEXFG
AFCOW
AFKBI
AFKRA
AFKRG
AFPKN
AFRWT
AIGRN
AJABX
AJEFB
AJMMQ
AJSCY
AJUZI
ALIPV
ALMA_UNASSIGNED_HOLDINGS
AOIJS
AUTPY
AYAKG
BAWUL
BCNDV
BDDNI
BENPR
BPHCQ
BSEHC
BVXVI
CBRKF
CCPQU
CORYS
CQQTX
CUTAK
D-I
DC.
DF.
DIK
E3Z
EBD
EBS
EF0
EJD
EMOBN
F5P
FYUFA
GROUPED_DOAJ
GROUPED_SAGE_PREMIER_JOURNAL_COLLECTION
H13
HMCUK
HYE
J8X
K.F
KQ8
L7B
MK0
O9-
P2P
PHGZM
PHGZT
PIMPY
PQQKQ
Q1R
ROL
RPM
S01
SAUOL
SCDPB
SCNPE
SFC
SV3
TR2
TUS
UKHRP
X7M
ZE2
ZGI
AAYXX
ACHEB
CITATION
OVT
CGR
CUY
CVF
ECM
EIF
NPM
3V.
7XB
8FK
AZQEC
DWQXO
K9.
PKEHL
PQEST
PQUKI
7X8
5PM
PUEGO
ID FETCH-LOGICAL-c528t-faf87a09fd63f1969314685b72e682a02812a825f20394d9bb8a06c50d53e8c93
IEDL.DBID AFRWT
ISSN 0300-0605
1473-2300
IngestDate Wed Aug 27 01:30:50 EDT 2025
Thu Aug 21 14:09:04 EDT 2025
Fri Jul 11 06:10:50 EDT 2025
Fri Jul 25 10:56:50 EDT 2025
Thu Apr 03 06:53:05 EDT 2025
Tue Jul 01 05:19:39 EDT 2025
Thu Apr 24 22:50:21 EDT 2025
Tue Jun 17 22:29:50 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 3
Keywords blood glucose
rat model
liver function protection
diabetes mellitus
Astragaloside IV
blood lipids
oxidative stress
Language English
License Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c528t-faf87a09fd63f1969314685b72e682a02812a825f20394d9bb8a06c50d53e8c93
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ORCID 0000-0002-5945-4731
OpenAccessLink https://journals.sagepub.com/doi/full/10.1177/0300060519841165?utm_source=summon&utm_medium=discovery-provider
PMID 33706619
PQID 2507474384
PQPubID 4451107
ParticipantIDs doaj_primary_oai_doaj_org_article_932e40de86b44c28bd2df4f98c558471
pubmedcentral_primary_oai_pubmedcentral_nih_gov_8166410
proquest_miscellaneous_2501268845
proquest_journals_2507474384
pubmed_primary_33706619
crossref_citationtrail_10_1177_0300060519841165
crossref_primary_10_1177_0300060519841165
sage_journals_10_1177_0300060519841165
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2021-03-01
PublicationDateYYYYMMDD 2021-03-01
PublicationDate_xml – month: 03
  year: 2021
  text: 2021-03-01
  day: 01
PublicationDecade 2020
PublicationPlace London, England
PublicationPlace_xml – name: London, England
– name: England
– name: London
– name: Sage UK: London, England
PublicationTitle Journal of international medical research
PublicationTitleAlternate J Int Med Res
PublicationYear 2021
Publisher SAGE Publications
Sage Publications Ltd
SAGE Publishing
Publisher_xml – name: SAGE Publications
– name: Sage Publications Ltd
– name: SAGE Publishing
References Chen, Gui, Chen 2008; 76
Li, Hou, Xu 2017; 31
Wang, Shao, Xu 2014; 36
Du, Zhang, Li 2018; 9
El Husseny, Mamdouh, Shaban 2017; 2017
Yu, Pan, Dong 2017; 1863
Wang, Chen, Yu 2018; 279
Zhou, Zhou, Wei 2017; 38
Qiao, Fan, Tang 2017; 11
Du, Xu, Gao 2018; 12
Inzucchi, Lipska, Mayo 2014; 312
Zhu, Zheng, Chen 2016; 37
Karam, Chavez-Moreno, Koh 2017; 16
Cai, Liu, Bian 2016; 12
Wang, Gan, Li 2017; 24
Defronzo 2009; 58
Khaki, Khaki, Hajhosseini 2014; 11
Wang, Li, Xiang 2017; 41
Miao, Liu, Wang 2017; 25
Tuhin, Begum, Rahman 2017; 17
Lee, Ma, Moulik 2018; 119
Qi, Gao, Hou 2017; 45
Chen, Wang, Wei 2016; 11
Song, Han, Sun 2018; 46
Robson, Kundur, Singh 2018; 12
Chatterjee, Khunti, Davies 2017; 389
Fox, Golden, Anderson 2015; 38
Gadelkarim, Abushouk, Ghanem 2018; 107
Li, Ding, Wu 2017; 44
Lei, Zhang, Li 2018; 12
Ghosh, Chowdhury, Sarkar 2018; 118
Mu, Zhang, Fan 2017; 25
bibr3-0300060519841165
bibr25-0300060519841165
bibr16-0300060519841165
bibr12-0300060519841165
bibr8-0300060519841165
bibr29-0300060519841165
bibr11-0300060519841165
bibr24-0300060519841165
bibr2-0300060519841165
bibr20-0300060519841165
bibr9-0300060519841165
bibr10-0300060519841165
bibr28-0300060519841165
bibr15-0300060519841165
Mu YP (bibr30-0300060519841165) 2017; 25
bibr1-0300060519841165
bibr23-0300060519841165
bibr32-0300060519841165
bibr19-0300060519841165
bibr5-0300060519841165
bibr27-0300060519841165
bibr14-0300060519841165
bibr6-0300060519841165
bibr31-0300060519841165
bibr18-0300060519841165
bibr22-0300060519841165
bibr21-0300060519841165
bibr26-0300060519841165
bibr4-0300060519841165
bibr7-0300060519841165
bibr13-0300060519841165
bibr17-0300060519841165
References_xml – volume: 44
  start-page: 2422
  year: 2017
  end-page: 2438
  article-title: Astragaloside IV prevents cardiac remodeling in the apolipoprotein E-deficient mice by regulating cardiac homeostasis and oxidative stress.
  publication-title: Cell Physiol Biochem
– volume: 107
  start-page: 625
  year: 2018
  end-page: 633
  article-title: Adipose-derived stem cells: effectiveness and advances in delivery in diabetic wound healing.
  publication-title: Biomed Pharmacother
– volume: 24
  start-page: 1111
  year: 2017
  end-page: 1120
  article-title: Circular RNA mediates cardiomyocyte death via miRNA-dependent upregulation of MTP18 expression.
  publication-title: Cell Death Differ
– volume: 11
  start-page: 2561
  year: 2016
  end-page: 2566
  article-title: Effects of astragalosides from Radix Astragali on high glucose-induced proliferation and extracellular matrix accumulation in glomerular mesangial cells.
  publication-title: Exp Ther Med
– volume: 41
  start-page: 1156
  year: 2017
  end-page: 1166
  article-title: Astragaloside alleviates hepatic fibrosis function via PAR2 signaling pathway in diabetic rats.
  publication-title: Cell Physiol Biochem
– volume: 12
  start-page: 455
  year: 2018
  end-page: 462
  article-title: Oxidative stress biomarkers in type 2 diabetes mellitus for assessment of cardiovascular disease risk.
  publication-title: Diabetes Metab Syndr
– volume: 45
  start-page: 1157
  year: 2017
  end-page: 1167
  article-title: Anti-inflammatory and immunostimulatory activities of astragalosides.
  publication-title: Am J Chin Med
– volume: 12
  start-page: 2785
  year: 2018
  end-page: 2793
  article-title: Astragaloside IV/lncRNA-TUG1/TRAF5 signaling pathway participates in podocyte apoptosis of diabetic nephropathy rats.
  publication-title: Drug Des Devel Ther
– volume: 11
  start-page: 3567
  year: 2017
  end-page: 3577
  article-title: Astragaloside IV protects rat retinal capillary endothelial cells against high glucose-induced oxidative injury.
  publication-title: Drug Des Devel Ther
– volume: 389
  start-page: 2239
  year: 2017
  end-page: 2251
  article-title: Type 2 diabetes.
  publication-title: Lancet
– volume: 12
  start-page: 2702
  year: 2016
  end-page: 2708
  article-title: Astragaloside IV ameliorates necrotizing enterocolitis by attenuating oxidative stress and suppressing inflammation via the vitamin D3-upregulated protein 1/NF-kappaB signaling pathway.
  publication-title: Exp Ther Med
– volume: 279
  start-page: 147
  year: 2018
  article-title: Circular RNA DLGAP4 ameliorates cardiomyocyte apoptosis through regulating BCL2 via targeting miR-143 in myocardial ischemia-reperfusion injury
  publication-title: Int J Cardiol
– volume: 11
  start-page: 1
  year: 2014
  end-page: 8
  article-title: The anti-oxidant effects of ginger and cinnamon on spermatogenesis dysfunction of diabetes rats.
  publication-title: Afr J Tradit Complement Altern Med
– volume: 58
  start-page: 773
  year: 2009
  end-page: 795
  article-title: Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus.
  publication-title: Diabetes
– volume: 2017
  start-page: 8095926
  year: 2017
  article-title: Adipokines: potential therapeutic targets for vascular dysfunction in type II diabetes mellitus and obesity.
  publication-title: J Diabetes Res
– volume: 9
  start-page: 15
  year: 2018
  article-title: Astragaloside IV inhibits adipose lipolysis and reduces hepatic glucose production via Akt dependent PDE3B expression in HFD-fed mice
  publication-title: Front Physiol
– volume: 17
  start-page: 423
  year: 2017
  article-title: Wound healing effect of Euphorbia hirta linn. (Euphorbiaceae) in alloxan induced diabetic rats
  publication-title: BMC Complement Altern Med
– volume: 37
  start-page: 1697
  year: 2016
  end-page: 1705
  article-title: Astragaloside IV facilitates glucose transport in C2C12 myotubes through the IRS1/AKT pathway and suppresses the palmitate-induced activation of the IKK/IkappaBalpha pathway.
  publication-title: Int J Mol Med
– volume: 25
  start-page: 477
  year: 2017
  end-page: 481
  article-title: The effect of different proportions of astragaloside and curcumin on DM model of mice.
  publication-title: Saudi Pharm J
– volume: 25
  start-page: 575
  year: 2017
  end-page: 582
  article-title: [Mechanism of astragaloside prevents cholestatic liver fibrosis through inhibition of Notch signaling activation].
  publication-title: Zhonghua Gan Zang Bing Za Zhi
– volume: 36
  start-page: 400
  year: 2014
  end-page: 406
  article-title: Astragaloside IV inhibits high glucose-induced cell apoptosis through HGF activation in cultured human tubular epithelial cells.
  publication-title: Ren Fail
– volume: 31
  start-page: 17
  year: 2017
  end-page: 36
  article-title: Research review on the pharmacological effects of astragaloside IV.
  publication-title: Fundam Clin Pharmacol
– volume: 76
  start-page: 796
  year: 2008
  end-page: 804
  article-title: Astragaloside IV improves high glucose-induced podocyte adhesion dysfunction via alpha3beta1 integrin upregulation and integrin-linked kinase inhibition.
  publication-title: Biochem Pharmacol
– volume: 16
  start-page: 120
  year: 2017
  article-title: Oxidative stress and inflammation as central mediators of atrial fibrillation in obesity and diabetes
  publication-title: Cardiovasc Diabetol
– volume: 118
  start-page: 272
  year: 2018
  end-page: 286
  article-title: Ameliorative role of ferulic acid against diabetes associated oxidative stress induced spleen damage.
  publication-title: Food Chem Toxicol
– volume: 119
  start-page: 69
  year: 2018
  end-page: 74
  article-title: Untimely oxidative stress in beta-cells leads to diabetes – role of circadian clock in beta-cell function.
  publication-title: Free Radic Biol Med
– volume: 38
  start-page: 1777
  year: 2015
  end-page: 1803
  article-title: Update on prevention of cardiovascular disease in adults with type 2 diabetes mellitus in light of recent evidence: a scientific statement from the American Heart Association and the American Diabetes Association.
  publication-title: Diabetes Care
– volume: 312
  start-page: 2668
  year: 2014
  end-page: 2675
  article-title: Metformin in patients with type 2 diabetes and kidney disease: a systematic review.
  publication-title: JAMA
– volume: 46
  start-page: 2883
  year: 2018
  end-page: 2897
  article-title: Astragaloside IV ameliorates early diabetic nephropathy by inhibition of MEK1/2-ERK1/2-RSK2 signaling in streptozotocin-induced diabetic mice.
  publication-title: J Int Med Res
– volume: 1863
  start-page: 1195
  year: 2017
  end-page: 1203
  article-title: Astragaloside IV attenuates lead acetate-induced inhibition of neurite outgrowth through activation of Akt-dependent Nrf2 pathway in vitro.
  publication-title: Biochim Biophys Acta Mol Basis Dis
– volume: 38
  start-page: 998
  year: 2017
  end-page: 1008
  article-title: Astragaloside IV attenuates free fatty acid-induced ER stress and lipid accumulation in hepatocytes via AMPK activation.
  publication-title: Acta Pharmacol Sin
– volume: 12
  start-page: 3517
  year: 2018
  end-page: 3524
  article-title: Combination of ginsenoside Rg1 and astragaloside IV reduces oxidative stress and inhibits TGF-beta1/Smads signaling cascade on renal fibrosis in rats with diabetic nephropathy.
  publication-title: Drug Des Devel Ther
– ident: bibr28-0300060519841165
  doi: 10.1016/j.bbadis.2017.03.006
– ident: bibr7-0300060519841165
  doi: 10.1016/j.dsx.2017.12.029
– ident: bibr19-0300060519841165
  doi: 10.1016/j.bcp.2008.06.020
– ident: bibr13-0300060519841165
  doi: 10.1142/S0192415X1750063X
– ident: bibr21-0300060519841165
  doi: 10.1016/j.jsps.2017.04.009
– ident: bibr24-0300060519841165
  doi: 10.2147/DDDT.S152489
– ident: bibr22-0300060519841165
  doi: 10.1111/fcp.12232
– ident: bibr18-0300060519841165
  doi: 10.3892/ijmm.2016.2555
– ident: bibr3-0300060519841165
  doi: 10.2337/dci15-0012
– ident: bibr25-0300060519841165
  doi: 10.3892/etm.2016.3629
– ident: bibr11-0300060519841165
  doi: 10.1155/2017/8095926
– ident: bibr16-0300060519841165
  doi: 10.2147/DDDT.S166525
– ident: bibr26-0300060519841165
  doi: 10.2147/DDDT.S171286
– ident: bibr2-0300060519841165
  doi: 10.1016/S0140-6736(17)30058-2
– ident: bibr27-0300060519841165
  doi: 10.1159/000486166
– ident: bibr6-0300060519841165
  doi: 10.1016/j.freeradbiomed.2018.02.022
– ident: bibr1-0300060519841165
  doi: 10.1016/j.ijcard.2018.09.023
– ident: bibr4-0300060519841165
  doi: 10.4314/ajtcam.v11i4.1
– ident: bibr5-0300060519841165
  doi: 10.1016/j.fct.2018.05.029
– ident: bibr8-0300060519841165
  doi: 10.1186/s12933-017-0604-9
– ident: bibr9-0300060519841165
  doi: 10.1016/j.biopha.2018.08.013
– ident: bibr14-0300060519841165
  doi: 10.3892/etm.2016.3194
– ident: bibr31-0300060519841165
  doi: 10.1038/aps.2016.175
– ident: bibr10-0300060519841165
  doi: 10.1186/s12906-017-1930-x
– ident: bibr17-0300060519841165
  doi: 10.3389/fphys.2018.00015
– ident: bibr20-0300060519841165
  doi: 10.1177/0300060518778711
– volume: 25
  start-page: 575
  year: 2017
  ident: bibr30-0300060519841165
  publication-title: Zhonghua Gan Zang Bing Za Zhi
– ident: bibr32-0300060519841165
  doi: 10.1159/000464122
– ident: bibr29-0300060519841165
  doi: 10.2337/db09-9028
– ident: bibr15-0300060519841165
  doi: 10.3109/0886022X.2013.867798
– ident: bibr23-0300060519841165
  doi: 10.1038/cdd.2017.61
– ident: bibr12-0300060519841165
  doi: 10.1001/jama.2014.15298
SSID ssj0042652
Score 2.3185117
Snippet Objectives To investigate the effects of astragaloside IV on blood glucose, blood lipids, and liver function in diabetic rats. Methods Fifty diabetic rats were...
To investigate the effects of astragaloside IV on blood glucose, blood lipids, and liver function in diabetic rats. Fifty diabetic rats were randomly placed...
Objectives To investigate the effects of astragaloside IV on blood glucose, blood lipids, and liver function in diabetic rats. Methods Fifty diabetic rats were...
To investigate the effects of astragaloside IV on blood glucose, blood lipids, and liver function in diabetic rats.OBJECTIVESTo investigate the effects of...
SourceID doaj
pubmedcentral
proquest
pubmed
crossref
sage
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 300060519841165
SubjectTerms Animals
Antioxidants - metabolism
Blood Glucose - metabolism
Diabetes
Diabetes Mellitus, Experimental - drug therapy
Glucose
Lipids
Liver
Liver - metabolism
Oxidative Stress
Pre-Clinical Research Report
Rats
Rodents
Saponins
Triterpenes
SummonAdditionalLinks – databaseName: DOAJ Directory of Open Access Journals
  dbid: DOA
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1La9wwEB5KTrmUvusmLSqUhcKatSXZlo9tSEgLLTlsSm5GT2oI3pDdHAL98Z2RH5tNX5deJdkM0oznG834G4B32sjAS6VTIiJMpSWbK32e5kFUqEJOm5gu-PK1PD2Xny-KizutvqgmrKcH7jdugfjCy8x5VRopLVfGcRdkqJUtKMMXAx_0eWMw1X-D0e0UfJuUXKAmE_EIohUliW9mxwlFrv7fAcxf6yTvFHtF_3PyCB4OwJF96AV-DA989wRmZz3z9O2cLbc_Uq3nbMbOtpzUt0_hx3IsKGd088o03XCgc1hRt0726Ru7JgpX71gsZGdDIfsch2Or-mnisr1qHb5fd44NFA-eRtEgGLlIOmbWdqy_0m0tQwVbP4Pzk-Pl0Wk6NF5IbcHVJg06qEpndXClCMSfI-gHrcJU3JeKa4QkOdcYWgaeiVq62hils9IWmSuEV7YWz2GvW3X-JTDubF0h5lEGAy9XlxoRjFbKOselk0ElsBhPorEDKzk1x7hs8pGI_N7ZJfB-euKqZ-T4y9qPdLjTOuLSjgOoYc2gYc2_NCyBw1E1msHA1w0iRwzEpFAygbfTNJom5Vt051c3cU2OdqAkyvGi16RJEiEqBHt5nUC1o2M7ou7OdO33SP9NmV6ZZwnMSBu3Iv1pE179j004gH1O1Tyx-u4Q9jbXN_41wrGNeRMt7yf2LC4x
  priority: 102
  providerName: Directory of Open Access Journals
– databaseName: Health & Medical Collection
  dbid: 7X7
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3da9RAEF-0vvgiWr-itawgB8KFSzabZPMkWlqqoPThKvcW9lMDJTnvrg8F_3hnNpvE86Ovs5swZGYyszOzvyHkjVTcsULIGIEIY67R5gqbxqnLSlAhI5UvF3z-Upxf8k-rfBUSbtvQVjn8E_2P2nQac-QLcNUQ-fJM8HfrHzFOjcLqahihcZfcQ-gy1OpyNR64wPnkoYqAw1WSfCpTLpCGJDhzc0Sg2XNLHr3_XyHn352Tv7V_eY909pA8CKEkfd_L_hG5Y9tDMrvosahv5nQ5Xa3azumMXkwo1TePyc_l0GJOMRdLJeY8wF10OL-TfvxKNwjqag31re00tLbPgeyH148LV826MfB-2RoaQB8sUsFEKDpNFDxtWtoneRtNQeW2T8jl2eny5DwOoxhinTOxi510opRJ5UyROUTUyfDKVq5KZgvBJAQpKZNw2HQsySpuKqWETAqdJybPrNBV9pQctF1rnxPKjK5KiIKEgqOYqQoJMY0UQhvDuOFORGQxSKLWAaccx2Vc1ekATf6H7CLydnxi3WN03LL3Awp33Ifo2p7Qbb7VwVhriGktT4wVheJcM6EMM467Sugcq8ppRI4G1aiDyW_rSUEj8npcBmPFCoxsbXft96RgGYIDH896TRo5ybISwr-0iki5p2N7rO6vtM13DwiOtV-eJhGZoTZOLP3vI7y4nf-X5D7Dzh3faXdEDnaba_sKQq-dOvb29QuSPiep
  priority: 102
  providerName: ProQuest
Title Treatment with astragaloside IV reduced blood glucose, regulated blood lipids, and protected liver function in diabetic rats
URI https://journals.sagepub.com/doi/full/10.1177/0300060519841165
https://www.ncbi.nlm.nih.gov/pubmed/33706619
https://www.proquest.com/docview/2507474384
https://www.proquest.com/docview/2501268845
https://pubmed.ncbi.nlm.nih.gov/PMC8166410
https://doaj.org/article/932e40de86b44c28bd2df4f98c558471
Volume 49
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV3da9swED_a9GUvY9_z2gUNRmAQL7Ys2_LTaEdCN1gJJd3yZmRJ3gKtU_LxEOgfvzvZTpZ1G3tJQFLiQ7qzfro7_Q7grSpEyROpfCIi9IUmm0ts6IdllKIKGVW4cMGXi-T8SnyextMDqNq7MM0MLt9TWhVK5F7WZN3kjR40QcYBaiYRiSD6kIL4Yz6sVzd57e1ui2pQC4Wn1zcU2daUD7nx29tth3DE0yTmHTg6HV1-m7Tvbtyu4ibuQOVYgngX2Lz3zL2NzPH9_wmk3s-1_CVhzO1ho0fwsAGf7LTWlsdwYKsn0BvX7NWbPpvsLmMt-6zHxjte681TuJu0SemMvLdMkZcEN5g5Vfxkn76yBdHAWsNcMjxrkuH72OzK3W87rme3M4P_ryrDGpoIS604d4y2WVIVNqtY7RaeaYZKunwGV6Ph5OO53xRv8HXM5covVSlTFWSlSaKSOHgiuuQVFym3ieQKYU3IFR5PSx5EmTBZUUgVJDoOTBxZqbPoOXSqeWVfAuNGZyniJlng4c1kiUIUpKTUxnBhRCk9GLQrkeuG2ZwKbFznYUtm_tvaefBu-4vbmtXjH2PPaHG344iP2zXMF9_zxrxzRMFWBMbKpBBCc1kYbkpRZlLHFIcOPThpVSNvVTxH9ImHORFJ4cGbbTeaN8VsVGXnazcmRFuSAuV4UWvSVpIoShEwhpkH6Z6O7Ym631PNfjgKcYoWizDwoEfauBPpb5Pw6n8HHsMDTlk_LkvvBDqrxdq-Rti2KrpwmE7TbmNx-H02vBhfdp0TBD-Ho-An-Xs_Cw
linkProvider SAGE Publications
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Jj9MwFLZGwwEuiJ3AAEaCSkiNmjhO4hwQYhu1zKI5dFBvwfEyRBolpe0IVeI38Rt5z1lKWeY2V9upnvp2v-fvEfJCFtyyREgfgQh9rlDnEhP6oY1SECEtC1cuODpOxqf80yye7ZCf3VsYbKvsbKIz1LpWeEc-AlcNkS-PBH8z_-bj1CisrnYjNBqxODDr75CyLV9PPgB_XzK2_3H6fuy3UwV8FTOx8q20IpVBZnUSWQSHifD1UVykzCSCSfC3IZOQN1kWRBnXWVEIGSQqDnQcGaEQfAlM_jVwvAEme-msT_DA2cVt1QKHuQTxpiw6wjVcghyfI-LNlht00wL-FeL-3an5W7uZ84D7t8jNNnSlbxtZu012THWHDE4a7Ov1kE43T7mWQzqgJxtU7PVd8mPatbRTvPulEu9YwD3VOC-UTj7TBYLIGk1dKz1tW-mHsHyGE8b6jfNyXmr4fVlp2oJMGFwFlaTopFHQaFnR5lK5VBREfHmPnF4Jk-6T3aquzENCmVZZClGXKCD101kiIYaSQiitGdfcCo-MOk7kqsVFx_Ec53nYQaH_wTuPvOq_mDeYIJecfYfM7c8hmrdbqBdneWsccoihDQ-0EUnBuWKi0ExbbjOhYqxihx7Z60Qjb03MMt8ohEee99tgHLDiIytTX7gzIWii4EDHg0aSekqiKIVwM8w8km7J2Bap2ztV-dUBkGOtmYeBRwYojRuS_vcnPLqc_mfk-nh6dJgfTo4PHpMbDLuGXJffHtldLS7MEwj7VsVTp2uUfLlq5f4FMPhi8A
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV3db9MwED9BJyFeEN8LDDASqoTU0MRxEudxfFQbH1OFOthb5MQ2RJrSqu0eJvHHc-c4LWWAeLWd6JS7y_3sO_8O4IWqhOWZVCEREYaiJp_LTBzGNsnRhLSqXLrg00l2dCren6VnvjaH7sL4L7h6RWVVKJH7WZN3L7Qd-xzjGA2TeEQQfEhB9DHXYU8I3OMNYO9w8vnrrP8VY_RJfRqBuqtE6TZPeeUdO3HJ0ff_CXNeLZ38pf7LhaTJbbjlsSQ77JR_B66Z9i4Mpx0Z9eWIzbZ3q1YjNmTTLU315T34MetrzBkdxjJFhx4YL-bUwJMdf2FLYnU1mrnaduZr20c47LrXbybOm0Wj8f2q1cyzPhgaRR9hFDVJ86xpWXfK29QMbW51H04n72ZvjkLfiyGsUy7XoVVW5ioqrM4SS5Q6Cd3ZSqucm0xyhSgl5gp3m5ZHSSF0UVVSRVmdRjpNjKyL5AEM2nlr9oFxXRc5wiBZ4V5MF5lCUKOkrLXmQgsrAxj3mihrT1RO_TLOy7jnJv9NdwG83Dyx6Eg6_rH2NSl3s47otd3AfPmt9N5aIqg1ItJGZpUQNZeV5toKW8g6pbRyHMBBbxplb7Elgkncm4lEigCeb6bRWykFo1ozv3BrYnQNKVCOh50lbSRJkhzxX1wEkO_Y2I6ouzNt890xglPyV8RRAEOyxq1If_sIj_534TO4MX07KT8en3x4DDc51fO4-rsDGKyXF-YJArJ19dS73U-dzCky
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Treatment+with+astragaloside+IV+reduced+blood+glucose%2C+regulated+blood+lipids%2C+and+protected+liver+function+in+diabetic+rats&rft.jtitle=Journal+of+international+medical+research&rft.au=Han%2C+Dong&rft.date=2021-03-01&rft.pub=SAGE+Publications&rft.issn=0300-0605&rft.eissn=1473-2300&rft.volume=49&rft.issue=3&rft_id=info:doi/10.1177%2F0300060519841165&rft.externalDocID=10.1177_0300060519841165
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0300-0605&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0300-0605&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0300-0605&client=summon